Edition:
United States

Pfizer's dermatitis treatment meets main goals of late-stage study


Wednesday, 15 May 2019 06:45am EDT 

May 15 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES POSITIVE TOP-LINE RESULTS FROM PHASE 3 STUDY OF INVESTIGATIONAL ORAL JAK1 CANDIDATE, ABROCITINIB (PF-04965842), IN PATIENTS AGED 12 AND OLDER WITH MODERATE TO SEVERE ATOPIC DERMATITIS.PFIZER- BY WEEK 12, PERCENT OF PATIENTS ACHIEVING CO-PRIMARY EFFICACY ENDPOINTS WITH EITHER DOSE WAS STATISTICALLY SIGNIFICANTLY HIGHER VERSUS PLACEBO .PFIZER- BY WEEK 12, PERCENT OF PATIENTS ACHIEVING EACH SECONDARY ENDPOINT WITH EITHER DOSE WAS STATISTICALLY SIGNIFICANTLY HIGHER VERSUS PLACEBO .PFIZER INC - STUDY ACHIEVES ALL CO-PRIMARY AND SECONDARY ENDPOINTS.PFIZER INC - RESULTS DEMONSTRATE RESPONSE TO TREATMENT FOR A STATISTICALLY SIGNIFICANT NUMBER OF PATIENTS.PFIZER INC - SAFETY RESULTS SHOW THAT BOTH DOSES OF ABROCITINIB WERE WELL-TOLERATED, AND THERE WERE NO UNEXPECTED SAFETY EVENTS.PFIZER - DISCONTINUATION RATES DUE TO AN ADVERSE EVENT WERE LOW IN EACH TREATMENT ARM (5.8% AND 5.8% IN 100MG AND 200MG) COMPARED TO PLACEBO (9.1%).